GLP-1 Clinical Trials Explained: How to Read Results
A patient-friendly guide to understanding the clinical trial data behind semaglutide, tirzepatide, and retatrutide.
When you read that semaglutide produces "14.9% body weight loss" or tirzepatide achieves "22.5% reduction," what do those numbers actually mean? And how do you compare results across different trials? This guide teaches you to read GLP-1 clinical data like a professional.
Trial Phases Explained
| Phase | Purpose | Size | Duration |
|---|---|---|---|
| Phase 1 | Safety, dosing | 20-100 | Weeks-months |
| Phase 2 | Efficacy, dose-finding | 100-500 | Months |
| Phase 3 | Confirm efficacy, safety | 1,000-10,000+ | 1-3 years |
| Phase 4 | Post-approval monitoring | Thousands+ | Ongoing |
Key Terms You Need to Know
- Randomized: Participants assigned to drug or placebo by chance (like flipping a coin)
- Double-blind: Neither patients nor doctors know who gets drug vs placebo
- Placebo-controlled: Comparison against an inactive treatment
- ITT (Intent-to-treat): Includes all participants, even dropouts -- more conservative estimate
- Completers analysis: Only includes participants who finished the study -- shows best-case results
- Primary endpoint: The main measurement the trial was designed to evaluate
- Statistical significance (p-value): p less than 0.05 means less than 5% chance the result is due to luck
How to Read Weight Loss Results
What to Look For
- Average % body weight lost: The headline number (e.g., -14.9% for STEP 1)
- Placebo-subtracted: How much more than placebo? (e.g., -12.5% net for STEP 1)
- Responder rates: What % achieved 5%, 10%, 15%, 20% thresholds?
- Study duration: Longer studies show more realistic results
- Dropout rate: High dropout (over 20%) weakens reliability
- Side effects: Rates of nausea, vomiting, discontinuation due to adverse events
Comparing Across Trials
Cross-trial comparison is tricky because different studies have different patient populations, different run-in periods, different lifestyle intervention intensities, and different analysis methods. The most reliable comparisons come from head-to-head trials (same study, same patients randomized to different drugs). For GLP-1 medications, no head-to-head of semaglutide 2.4mg vs tirzepatide 15mg has been published as of 2026, so cross-trial comparisons must be interpreted cautiously.
Evidence-Based Treatment
Trimi offers medications backed by the strongest clinical evidence. Semaglutide $99/mo. Tirzepatide $125/mo.
Get StartedMedical Disclaimer
This article simplifies clinical trial methodology for patient understanding. Consult published trial manuscripts for complete data. Always discuss treatment options with your healthcare provider.
More on GLP-1 reference
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).